MedTrace Logo

A Study of XMT-2056 in Advanced/Recurrent Solid Tumors That Express HER2

NCT05514717 · Status: RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 162

Last updated 2025-07-11

No results posted yet for this study

Summary

A Study of XMT-2056 in advanced/recurrent solid tumors that express HER2.

Conditions

Interventions

DRUG

XMT-2056

XMT-2056 will be administered through a vein in your arm or port catheter (intravenously)

Sponsors & Collaborators

  • Mersana Therapeutics

    lead INDUSTRY

Principal Investigators

  • Brad Sumrow, MD · Mersana Therapeutics

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-01-24
Primary Completion
2027-04-30
Completion
2027-04-30
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05514717 on ClinicalTrials.gov